Efineptakin alfa Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Efineptakin alfa comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including AIDS-related Kaposi sarcoma. Most recent publication: Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma., J Immunother Cancer, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
    Ramaswami R, Kask AS, D'Amico L, et al. · J Immunother Cancer · 2025
    PubMed: PMID 39915263 · NCT04893018 · AIDS-related Kaposi sarcoma

Publications by year

2025–2025: 1 publications.

2025
1

Publications by indication

  • Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
    J Immunother Cancer · 2025 · PMID 39915263 · NCT04893018

Publications by journal

  • J Immunother Cancer1 paper

All Efineptakin alfa publications (1)

2025 (1 paper)

  1. Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
    Ramaswami R, Kask AS, D'Amico L, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 39915263 · NCT04893018 · AIDS-related Kaposi sarcoma

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 02 Jun 2026 16:20:39 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).